Assertio Therapeutics Inc Market Cap ($151.86 Million)
Market Cap & Net Worth: Assertio Therapeutics Inc (ASRT)
Assertio Therapeutics Inc market cap. Assertio Therapeutics Inc (NASDAQ:ASRT) has a market capitalization of $151.86 Million ($151.86 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17440 globally and #4140 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Assertio Therapeutics Inc's stock price $23.50 by its total outstanding shares 6462180 (6.46 Million). Also see ASRT cash flow conversion for how efficiently the company converts equity into cash flow.
Assertio Therapeutics Inc Market Cap History (2015–2026)
Assertio Therapeutics Inc market cap history from 2015 to 2026. Data shows change from $468.64 Million to $151.86 Million (-11.07% CAGR). Check ASRT share price today for real-time trading data and today's change.
Index Memberships
Assertio Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.01% | #476 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1698 of 3165 |
Weight: Assertio Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Assertio Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Assertio Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Assertio Therapeutics Inc equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.49x
Assertio Therapeutics Inc's market cap is 0.49 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $465.79 Million | $455.90 Million | -$88.72 Million | 1.02x | N/A |
| 2017 | $208.08 Million | $380.72 Million | -$102.50 Million | 0.55x | N/A |
| 2018 | $93.31 Million | $311.77 Million | $36.91 Million | 0.30x | 2.53x |
| 2019 | $32.31 Million | $229.53 Million | -$217.20 Million | 0.14x | N/A |
| 2020 | $9.24 Million | $108.08 Million | -$28.14 Million | 0.09x | N/A |
| 2021 | $14.09 Million | $111.01 Million | -$1.28 Million | 0.13x | N/A |
| 2022 | $27.79 Million | $156.23 Million | $109.62 Million | 0.18x | 0.25x |
| 2023 | $6.91 Million | $152.07 Million | -$331.94 Million | 0.05x | N/A |
| 2024 | $5.63 Million | $124.96 Million | -$21.58 Million | 0.05x | N/A |
| 2025 | $58.61 Million | $118.71 Million | -$30.38 Million | 0.49x | N/A |
Competitor Companies of ASRT by Market Capitalization
Companies near Assertio Therapeutics Inc in the global market cap rankings as of November 5, 2026. Also see ASRT total assets for a full breakdown of the balance sheet.
Key companies related to Assertio Therapeutics Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Assertio Therapeutics Inc (2015–2026)
Market capitalization of Assertio Therapeutics Inc from 2015 to today. Between 2015 and today, Assertio Therapeutics Inc's market cap moved from $468.64 Million to $ 151.86 Million, with a yearly change of -11.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $151.86 Million | +159.10% |
| 2025 | $58.61 Million | +941.21% |
| 2024 | $5.63 Million | -18.59% |
| 2023 | $6.91 Million | -75.12% |
| 2022 | $27.79 Million | +97.25% |
| 2021 | $14.09 Million | +52.40% |
| 2020 | $9.24 Million | -71.39% |
| 2019 | $32.31 Million | -65.37% |
| 2018 | $93.31 Million | -55.16% |
| 2017 | $208.08 Million | -55.33% |
| 2016 | $465.79 Million | -0.61% |
| 2015 | $468.64 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Assertio Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $151.86 Million USD |
| MoneyControl | $151.86 Million USD |
| MarketWatch | $151.86 Million USD |
| marketcap.company | $151.86 Million USD |
| Reuters | $151.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more